Opella North America

Last updated
Chattem, Inc.
Company type Subsidiary
Industry Healthcare
Over-the-counter-drug manufacturing
Founded Tennessee (January 30, 1879, as the Chattanooga Medicine Company)
Headquarters
Chattanooga, Tennessee
Key people
Products Allegra, Gold Bond, ACT Mouthwash, Cortizone-10, Flexall, IcyHot, Sun-In, Ultra Swim, Pamprin, Premsyn, Kaopectate, Dexatrim, Aspercreme, Selsun Blue, Nasacort, Unisom, Capzasin, Benzodent, Herpecin-L, Garlique, and New Phase
Revenue$1 Billion (USD) (2013)
Owner Opella
Number of employees
536 [1]
Parent Opella
Website opella.com/en

Chattem, Inc., doing business as Opella North America, is an American, Chattanooga, Tennessee-based, producer and marketer of over-the-counter healthcare products, toiletries, dietary supplements, topical analgesics, and medicated skin care products. The company is a subsidiary of the French multinational pharmaceutical company Sanofi until 2024, now a subsidiary of the French-American multinational pharmaceutical company Opella.

Contents

Originally named the Chattanooga Medicine Company, the company’s brand portfolio holds twenty-two brands including Allegra, Gold Bond, Flexall, IcyHot, Rolaids, Sun-In, Pamprin, Dexatrim, Aspercreme, and Selsun Blue. The company produces two-thirds of its products at its Chattanooga production facilities with the remaining produced by third-party producers.

The company’s brands are sold nationally through mass merchandiser, drug and food retailers. In 2005, 70% of the firm's sales were made through its top ten customers, which include Wal-Mart, Walgreens, and Kroger. Sales to Wal-Mart constituted 36% of Chattem’s total sales in 2005. Chattem supports these sales with a forty-five-person sales force and broadcast media advertising. Chattem has market penetration in the United States, Europe, Canada, Latin America, and the Caribbean.

History

Recent events

In October 2006, Chattem announced it would acquire five brands for $410 million as a result of the merger between Johnson & Johnson and the consumer healthcare business of Pfizer. These brands are:

Pending the US government’s approval of the merger of Johnson & Johnson and Pfizer Consumer Healthcare, Chattem will acquire five brands divested from the firms. Chattem has announced it expects to take possession of the brands around January 2007. These mature brands will provide $150 million in additional revenue to Chattem per year.[ citation needed ]

On December 21, 2009, Paris-based (France) Sanofi, the world's fourth largest drugmaker, said it was acquiring Chattem in a $1.9 billion cash deal. Sanofi said the acquisition would be completed by the first quarter of 2010. [6]

In 2020, Sanofi Consumer Healthcare (CHC), based in Neuilly-sur-Seine near Paris, became Opella, with the ultimate goal of being sold by the French pharmaceutical group Sanofi. Sanofi Consumer Healthcare North America (Chattem, Inc.) then adopted the name Opella.

In 2024, Sanofi announced the sale of 50% of Opella (including Chattem) to the American private equity company CD&R. Sanofi retained 48.2% and Bpifrance (the French government's public investment bank) acquired 1.2%. [7]

Current brands

Chattem manufactures many over-the-counter healthcare products. They are marketed in three categories: pain relief, skin & hair care, and health & wellness.

Pain relief

Skin & hair care

Health & wellness

References

  1. "Archived copy" (PDF). Archived from the original (PDF) on 2012-05-08. Retrieved 2011-11-12.{{cite web}}: CS1 maint: archived copy as title (link)
  2. "Chattem". Archived from the original on 2011-11-02. Retrieved 2011-11-12.
  3. Friedman, Alexi (8 January 2013). "Johnson & Johnson sells its troubled Rolaids brand to Sanofi". The Star-Ledger . Retrieved 9 September 2013.
  4. Pare, Mike (9 January 2013). "Rolaids next on Chattanooga-based Chattem's plate". Chattanooga Times Free Press . Retrieved 9 September 2013.
  5. "NVE Pharmaceuticals Announces the Acquisition of Dexatrim to the Stacker2 Family". PRWeb. March 11, 2014. Retrieved September 26, 2018.
  6. "Sanofi to Acquire Chattem", The Economic Times (December 22, 2009)
  7. Kollewe, Julia; Jolly, Jasper (2024-10-21). "France warns US buyer of Sanofi division of penalties for shifting production abroad". The Guardian. ISSN   0261-3077 . Retrieved 2025-11-29.

Official website